DrugPatentWatch Database Preview
Litigation Details for ELI LILLY AND COMPANY v. ACTAVIS ELIZABETH LLC (D.N.J. 2007)
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
ELI LILLY AND COMPANY v. ACTAVIS ELIZABETH LLC (D.N.J. 2007)
Docket | Start Trial | Date Filed | 2007-08-09 |
Court | District Court, D. New Jersey | Date Terminated | 2010-08-25 |
Cause | 35:183 Patent Infringement | Assigned To | Dennis M. Cavanaugh |
Jury Demand | Defendant | Referred To | Magistrate Judge Joseph A. Dic |
Parties | ACTAVIS ELIZABETH LLC; APOTEX CORP.; APOTEX, INC.; AUROBINDO; CHAMBERLAIN COMMUNICATIONS GROUP, LLC; ELI LILLY AND COMPANY; GLENMARK PHARMACEUTICALS INC., USA; MYLAN PHARMACEUTICALS INC.; SANDOZ INC.; SUN PHARMACEUTICALS; SYNTHON LABORATORIES, INC.; TEVA PHARMACEUTICALS; ZYDUS PHARMACEUTICALS USA INC. | ||
Patents | 10,183,005; 4,018,895; 4,194,009; 4,314,081; 4,626,549; 4,663,318; 5,631,021; 5,658,590; 6,297,014; 6,326,018; 6,433,003; 7,078,020; 7,417,022; 8,217,012; 8,399,015; 8,445,018; 8,624,003; 9,081,016; 9,297,018; 9,399,025; 9,574,010; 9,616,024 | ||
Attorneys | ARNOLD B. CALMANN; ARTHUR L. LESSLER; BRIAN JEFFREY ROBINSON; CHRISTOPHER G. FITZPATRICK; DAVID J. COONER; ERIC I. ABRAHAM; FRANK HOLAHAN; GREGORY D. MILLER; JAMES E. CECCHI; JAMES S. FRIEDMAN; JAMES S. RICHTER; JANE JHUN; JEFFREY S. SOOS; JOHN C. GARDE; JOHN F. BRENNER; JOSEPH NICHOLAS FROEHLICH; KATHERINE ANN ESCANLAR; KEVIN MICHAEL RYAN; MAYRA VELEZ TARANTINO; MELISSA ANNE CHUDEREWICZ; MELISSA E. FLAX; MELISSA STEEDLE BOGAD; MICHAEL ANDREW HOLTMAN; MICHAEL E. PATUNAS; PAUL L. KATTAS; STEVEN J. LEE; VICTORIA ELIZABETH SPATARO | ||
Firms | Alston & Bird LLP; Carella, Byrne, Cecchi, Olstein, Brody & Agnello, P.C.; Carella, Byrne, Cecchi, Olstein, Brody & Agnello, PC; Eric I. Abraham; Finnegan Henderson Farabow Garrett and Dunner; Goodwin Procter LLP, the New York Times Building; Kelley Drye Warren, LLP; Kenyon & Kenyon LLP; Lessler & Lessler; McCarter & English, LLP; McElroy, Deutsch, Mulvaney & Carpenter, LLC; Pepper Hamilton LLP; Reppert Kelley; Saiber, LLC; Smith, Gambrell & Russell, LLP | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in ELI LILLY AND COMPANY v. ACTAVIS ELIZABETH LLC
Biologic Drugs cited in ELI LILLY AND COMPANY v. ACTAVIS ELIZABETH LLC
The biologic drugs covered by the patents cited in this case are Start Trial , Start Trial , Start Trial , Start Trial , Start Trial , Start Trial , Start Trial , Start Trial , Start Trial , Start Trial , Start Trial , Start Trial , Start Trial , Start Trial , Start Trial , Start Trial , Start Trial , Start Trial , Start Trial , Start Trial , Start Trial , Start Trial , Start Trial , Start Trial , Start Trial , Start Trial , Start Trial , Start Trial , Start Trial , Start Trial , Start Trial , Start Trial , Start Trial , Start Trial , Start Trial , and Start Trial .
Details for ELI LILLY AND COMPANY v. ACTAVIS ELIZABETH LLC (D.N.J. 2007)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
2008-07-15 | 190 | infringement of U.S. Pat. No. 5,658,590 (“the ‘590 patent”). The ‘590 patent covers a method of using the… will not have patent prosecution responsibilities for current or future Lilly patent applications concerning… BACKGROUND Eli Lilly brought this patent infringement action against defendants alleging…preparation or prosecution of any patent application that covers tomoxetine or atomoxetine…plaintiff’s in-house counsel from prosecuting patent applications for the duration of this action and | External link to document | |
2009-05-21 | 331 | of treatment patent. On August 19, 1997, U.S. Patent No. 5,658,590 (the “‘590 Patent”), titled “Treatment…atomoxetine before the ‘590 Patent expires. Lilly initiated this action for patent infringement under 35 U.S.C…expiration of the ‘590 Patent would constitute further infringement of the ‘590 Patent under 35 U.S.C. §§ … D. Tollefson and assigned to Lilly. The ‘590 Patent contains 16 claims. Claim 1 is the only independent…methods of treating ADHD. Notably, the ‘590 Patent claims do not and could not include tomoxetine. | External link to document | |
2009-09-16 | 474 | for Summary Judgment of Invalidity of U.S. Patent No. 5,658,590, Defendants’ Response to Eli Lilly and Cornpany… Surnmary Judgment of Invalidity of U.S. Patent No. 5,658,590, and Exhibits BBB, CCC and III that accompany…for Summary Judgment cf Invalidity of U.S. Patent No. 5,658,590, all of which were filed on July 27, 2009…for Summary Judgment of Invalidity cf U.S. Patent No. 5,658,590 and Defendants’ Response to Eli Lilly and…for Summary Judgment of Invalidity of U.S. Patent No. 5,658,590, along with Exhibits BBB, CCC and III that | External link to document | |
2009-09-16 | 475 | Response l. Lilly's U.S. Patent No. 5,658,590 ("'590 patent") is entitled "Treatment…hydrochloride. (See Pliszka, Ex. B, U.S. Patent No. 5,658,590(f1led Jan. ll, 1995).) Undisputed. …tomoxetine." (See Pliszka, Ex. B, '590 patent at claim l, col. 4, ll. 24-26.) Claims 2-16 depend…to respond. 4. The claims of the '590 patent cover the only FDA- approved use of Strattera® …Lilly submitted information concerning the '590 patent to the FDA in Undisputed. Page 2 of 22 | External link to document | |
2009-12-31 | 494 | Additionally, Defendants assert that U.S. Patent Nos. 4,018,895, 4,194,009, and 4,626,549 were not properly… prosecution of another patent (“the ‘985 Patent”). The ‘985 Patent pertains to a method of… the patent (i.e., to induce others to violate the patent by using atomextine in the patented manner… alleged infringement of U.S. Patent No. 5,658,590 (“the ‘590 Patent”). … known as atomoxetine. The ‘590 Patent is a method-of-use patent which claims methods of treating Attention | External link to document | |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |